oral MET kinase inhibitor
approved for clinical use in NSCLC
internal HTS and SBDD
Clinical Cancer Research
Merck KGaA
tepotinib
9. The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both…